Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells 503 Shares of Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Jeffrey William Henderson sold 503 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $64.05, for a total transaction of $32,217.15. Following the transaction, the director now directly owns 33,108 shares of the company's stock, valued at $2,120,567.40. This trade represents a 1.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, March 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $58.69, for a total value of $293,450.00.
• On Monday, February 3rd, Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00.
• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00.

Halozyme Therapeutics Trading Down 3.5 %

Halozyme Therapeutics stock traded down $2.15 during trading hours on Friday, hitting $59.77. The company had a trading volume of 2,295,325 shares, compared to its average volume of 1,393,194. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The firm has a market cap of $7.38 billion, a P/E ratio of 17.43, a P/E/G ratio of 0.42 and a beta of 1.32. The company has a 50-day moving average price of $59.82 and a two-hundred day moving average price of $54.82. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $66.00.

Remove Ads

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on HALO shares. HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Benchmark reiterated a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Finally, Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $62.78.

Hedge Funds Weigh In On Halozyme Therapeutics

Institutional investors have recently made changes to their positions in the company. Norges Bank bought a new position in Halozyme Therapeutics during the 4th quarter worth about $60,054,000. Capital World Investors purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth approximately $35,773,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock valued at $47,470,000 after purchasing an additional 581,475 shares in the last quarter. D. E. Shaw & Co. Inc. increased its holdings in Halozyme Therapeutics by 171.2% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 831,414 shares of the biopharmaceutical company's stock valued at $39,750,000 after buying an additional 524,802 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Halozyme Therapeutics in the fourth quarter worth approximately $21,838,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.